Literature DB >> 27009627

Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy.

Akinori Nakamura1,2, Noboru Fueki3, Naoko Shiba4, Hirohiko Motoki5, Daigo Miyazaki1,2, Hitomi Nishizawa6, Yusuke Echigoya7, Toshifumi Yokota7, Yoshitsugu Aoki8, Shin'ichi Takeda8.   

Abstract

Few cases of dystrophinopathy show an asymptomatic phenotype with mutations in the 5' (exons 3-7) hot spot in the Duchenne muscular dystrophy (DMD) gene. Our patient showed increased serum creatine kinase levels at 12 years of age. A muscle biopsy at 15 years of age led to a diagnosis of Becker muscular dystrophy. The patient showed a slight decrease in cardiac function at the age of 21 years and was administered a β-blocker, but there was no muscle involvement even at the age of 27 years. A deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene was detected, and dystrophin protein expression was ∼15% that of control level. We propose that in-frame deletion of exons 3-9 may produce a functional protein, and that multiexon skipping therapy targeting these exons may be feasible for severe dystrophic patients with a mutation in the 5' hot spot of the DMD gene.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27009627     DOI: 10.1038/jhg.2016.28

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  27 in total

1.  Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.

Authors:  Toshifumi Yokota; Qi-Long Lu; Terence Partridge; Masanori Kobayashi; Akinori Nakamura; Shińichi Takeda; Eric Hoffman
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

2.  Dystrophin and Duchenne dystrophy.

Authors:  Victor Dubowitz; Ronald D Cohn
Journal:  Neuromuscul Disord       Date:  2015-05       Impact factor: 4.296

3.  Muscular dystrophy in a litter of golden retriever dogs.

Authors:  J N Kornegay; S M Tuler; D M Miller; D C Levesque
Journal:  Muscle Nerve       Date:  1988-10       Impact factor: 3.217

Review 4.  Dystrophies and heart disease.

Authors:  G F Cox; L M Kunkel
Journal:  Curr Opin Cardiol       Date:  1997-05       Impact factor: 2.161

5.  Alternate binding of actin and calmodulin to multiple sites on dystrophin.

Authors:  H W Jarrett; J L Foster
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

6.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Authors:  M Koenig; A H Beggs; M Moyer; S Scherpf; K Heindrich; T Bettecken; G Meng; C R Müller; M Lindlöf; H Kaariainen; A de la Chapellet; A Kiuru; M L Savontaus; H Gilgenkrantz; D Récan; J Chelly; J C Kaplan; A E Covone; N Archidiacono; G Romeo; S Liechti-Gailati; V Schneider; S Braga; H Moser; B T Darras; P Murphy; U Francke; J D Chen; G Morgan; M Denton; C R Greenberg; K Wrogemann; L A Blonden; M B van Paassen; G J van Ommen; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

7.  Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a "mild Becker" phenotype.

Authors:  K Corrado; J A Rafael; P L Mills; N M Cole; J A Faulkner; K Wang; J S Chamberlain
Journal:  J Cell Biol       Date:  1996-08       Impact factor: 10.539

8.  Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human.

Authors:  Marcella Neri; Silvia Torelli; Sue Brown; Isabella Ugo; Patrizia Sabatelli; Luciano Merlini; Pietro Spitali; Paola Rimessi; Francesca Gualandi; Caroline Sewry; Alessandra Ferlini; Francesco Muntoni
Journal:  Neuromuscul Disord       Date:  2007-09-07       Impact factor: 4.296

9.  Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice.

Authors:  Yusuke Echigoya; Yoshitsugu Aoki; Bailey Miskew; Dharminder Panesar; Aleksander Touznik; Tetsuya Nagata; Jun Tanihata; Akinori Nakamura; Kanneboyina Nagaraju; Toshifumi Yokota
Journal:  Mol Ther Nucleic Acids       Date:  2015-02-03       Impact factor: 10.183

10.  Targeted exon skipping to correct exon duplications in the dystrophin gene.

Authors:  Kane L Greer; Hanns Lochmüller; Kevin Flanigan; Susan Fletcher; Steve D Wilton
Journal:  Mol Ther Nucleic Acids       Date:  2014-03-18       Impact factor: 10.183

View more
  16 in total

Review 1.  What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2019-07-09       Impact factor: 2.698

2.  Genotype-phenotype correlation in Becker muscular dystrophy in Chinese patients.

Authors:  Ruiyi Yuan; Junfei Yi; Zhiying Xie; Yimeng Zheng; Miao Han; Yue Hou; Zhaoxia Wang; Yun Yuan
Journal:  J Hum Genet       Date:  2018-07-05       Impact factor: 3.172

3.  Functional correction of dystrophin actin binding domain mutations by genome editing.

Authors:  Viktoriia Kyrychenko; Sergii Kyrychenko; Malte Tiburcy; John M Shelton; Chengzu Long; Jay W Schneider; Wolfram-Hubertus Zimmermann; Rhonda Bassel-Duby; Eric N Olson
Journal:  JCI Insight       Date:  2017-09-21

4.  Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.

Authors:  Rika Maruyama; Toshifumi Yokota
Journal:  Methods Mol Biol       Date:  2021

Review 5.  Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.

Authors:  Akinori Nakamura
Journal:  J Hum Genet       Date:  2017-06-01       Impact factor: 3.172

Review 6.  Large in-frame 5' deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature.

Authors:  Elizabeth M Gibbs; Florian Barthélémy; Emilie D Douine; Natalie C Hardiman; Perry B Shieh; Negar Khanlou; Rachelle H Crosbie; Stanley F Nelson; M Carrie Miceli
Journal:  Neuromuscul Disord       Date:  2019-09-24       Impact factor: 4.296

Review 7.  Skipping Multiple Exons to Treat DMD-Promises and Challenges.

Authors:  Tejal Aslesh; Rika Maruyama; Toshifumi Yokota
Journal:  Biomedicines       Date:  2018-01-02

Review 8.  Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy.

Authors:  Akinori Nakamura
Journal:  J Pers Med       Date:  2019-03-04

9.  CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene.

Authors:  Tatiana V Egorova; Evgenia D Zotova; Denis A Reshetov; Anna V Polikarpova; Svetlana G Vassilieva; Dmitry V Vlodavets; Alexey A Gavrilov; Sergey V Ulianov; Vladimir L Buchman; Alexei V Deykin
Journal:  Dis Model Mech       Date:  2019-04-25       Impact factor: 5.758

10.  Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.

Authors:  Yusuke Echigoya; Akinori Nakamura; Tetsuya Nagata; Nobuyuki Urasawa; Kenji Rowel Q Lim; Nhu Trieu; Dharminder Panesar; Mutsuki Kuraoka; Hong M Moulton; Takashi Saito; Yoshitsugu Aoki; Patrick Iversen; Peter Sazani; Ryszard Kole; Rika Maruyama; Terry Partridge; Shin'ichi Takeda; Toshifumi Yokota
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.